(Q34611004)

3 August 2017

1 reference

title

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

1 reference

Joachim Stangier

1

1 reference

3 August 2017

Andreas Clemens

series ordinal

2

1 reference

3 August 2017

publication date

19 August 2009

1 reference

Clinical and Applied Thrombosis-Hemostasis

3 August 2017

published in

1 reference

3 August 2017

volume

15 Suppl 1

1 reference

3 August 2017

page(s)

9S-16S

1 reference

Triggers, targets and treatments for thrombosis

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Dabigatran etexilate: future directions in anticoagulant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609343004

21 January 2018

Identifiers

DOI

10.1177/1076029609343004

1 reference

3 August 2017

1 reference